Status:
COMPLETED
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Samsung Medison
Conditions:
Fatty Liver
Fatty Liver, Nonalcoholic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate diagnostic performance of quantitative ultrasonographic parameters for the assessment of hepatic steatosis with find optimal cut-off values in patients with no...
Eligibility Criteria
Inclusion
- patients with known NAFLD or suspected of having NAFLD
- Patients who are scheduled hepatectomy for living donor liver donation
- aged ≥ 18 years who are willing and able to complete all procedures
Exclusion
- excessive alcohol consumption within 2 years (40g/day for men, 20g/day for women)
- clinical, laboratory, or histologic evidence of a liver disease other than NAFLD, including viral hepatitis, autoimmune hepatitis, or genetic or acquired disorders
- use of steatogenic or hepatotoxic medication
- evidence of decompensated liver disease
- history of liver surgery
- contraindication to MRI
- any other condition believed by investigator to affect a patients' compliance, or completion of the study
Key Trial Info
Start Date :
July 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2021
Estimated Enrollment :
173 Patients enrolled
Trial Details
Trial ID
NCT04462562
Start Date
July 3 2020
End Date
June 29 2021
Last Update
March 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea